menu

ReachMD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Refractory mCRC Care: A Combination Therapy Approach Improves Survival

ReachMD Healthcare Image
Restart
Resume
Choose a format
Media formats available:
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Related
Comments
  • Sponsored by

  • Overview

    The SUNLIGHT trial examined the efficacy and safety of combining trifluridine–tipiracil and bevacizumab and found that this approach improved overall survival and progression-free survival in patients with refractory metastatic colorectal cancer (mCRC). Here to share insights on the SUNLIGHT trial’s design and findings is Dr. Marwan Fakih, Professor in the Department of Medical Oncology and Therapeutics Research at City of Hope Comprehensive Cancer Center.

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Sponsored by

  • Overview

    The SUNLIGHT trial examined the efficacy and safety of combining trifluridine–tipiracil and bevacizumab and found that this approach improved overall survival and progression-free survival in patients with refractory metastatic colorectal cancer (mCRC). Here to share insights on the SUNLIGHT trial’s design and findings is Dr. Marwan Fakih, Professor in the Department of Medical Oncology and Therapeutics Research at City of Hope Comprehensive Cancer Center.

Facebook Comments

Schedule28 May 2024